Skip to main content

Table 4 Subgroup analyses of the relationships between Nestin expression and overall survival or progression-free-survival

From: Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis

Comparison variables Overall survival Progression-free survival
Number of studies, Heterogeneity (I2 statistics; %) HR 95 % CI, P value Interaction, P value Number of studies, Heterogeneity (I2 statistics; %) HR 95 % CI, P value Interaction, P value
Total 8 (75.8) 1.75 (1.19–2.58), 0.004 NA 5 (71.5) 1.55 (0.96–2.51), 0.074 NA
Origin country       
Europe 5 (73.1) 1.52 (1.04–2.21), 0.029 0.014 4 (74.1) 1.76 (0.98–3.14), 0.057 0.142
Asian 2 (81.8) 1.92 (0.43–8.62), 0.393   1 (NA) 1.55 (0.96–2.51), 0.973  
USA 1 (NA) 13.42 (2.56–70.34), 0.002     
Sample size       
>50 5 (71.6) 1.41 (1.00–1.98), 0.051 0.005 3 (82.6) 1.39 (0.77–2.50), 0.277 0.322
≤50 3 (71.2) 3.61 (0.99–13.17), 0.052   2 (36.5) 2.14 (0.85–5.35), 0.105  
Follow up period       
1,>media 12months 2 (68.7) 4.96 (1.08–22.78), 0.040 0.001 1 (NA) 2.40 (1.60–3.40), 0.000 0.008
2,≤media 12months 3 (68.8) 1.64 (0.74–3.67), 0.225   3 (55.4) 1.49 (0.76–2.94), 0.246  
3,No Referreed 3 (66.8) 1.35 (0.77–2.38), 0.300   1 (NA) 1.01 (0.57–1.79), 0.973  
Median/mean age y       
Referred 3 (83.4) 3.36 (0.72–15.61), 0.123 0.154 1 (NA) 1.01 (0.57–1.80), 0.973 0.142
No Referred 5 (75.8) 1.52 (1.04–2.21), 0.029   4 (74.7) 1.76 (0.98–3.14), 0.057  
Test method       
IHC 5 (82.1) 2.11 (1.10–4.04), 0.025 0.671 2 (83.6) 1.60 (0.69–3.73), 0.275 0.063
Others 3 (68.8) 1.64 (0.74–3.67), 0.225   3 (55.4) 1.49 (0.76–2.51), 0.246  
Cut‑off level       
1:median 5 (74.1) 1.55 (1.00–2.42), 0.050 0.021 3 (55.4) 1.49 (0.76–2.94), 0.246 0.063
2:others 3 (75.6) 2.10 (0.88–5.00), 0.093   2 (83.6) 1.60 (0.69–3.73), 0.275  
WHO grade       
IV 2 (0.0) 1.09 (0.83–1.44), 0.518 0.000 2 (0.00) 1.04 (0.77–1.41), 0.808 0.000
II–III 4 (57.2) 3.11 (1.45–6.67), 0.004   3 (0.00) 2.34 (1.68–3.27), 0.000